Astellas Pharma today announced that the US Food and Drug Administration (FDA) has approved VYLOY (zolbetuximab-clzb) in ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved VYLOY™ (zolbetuximab-clzb) in combination ...

Program for Cancer and Cell Biology, Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences; Peking University International Cancer Institute; and State Key Laboratory ...

International Multi-site Study of Ibex Medical Analytics’ AI-powered Solution Demonstrates Improved HER2 Biomarker Scoring in Breast Cancer ...

The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.

RxDx Assay to identify patients with gastric or GEJ cancer gets CE Mark approval: Basel Friday, October 11, 2024, ...

The IHC companion diagnostic test determines CLDN18 protein expression and may help identify patients who are eligible for treatment with Vyloy.

The immunohistochemistry (IHC) market is on a promising growth trajectory, with an anticipated value of USD 3.5 billion in ...

Daiichi Sankyo submits Enhertu sNDA to Japan’s MHLF for patients with HER2 low or HER2 ultralow metastatic breast cancer ...

ISLAMABAD: As daily life is paralysed in Islamabad as the PTI workers clashes with police continued for the second day on Saturday, the Islamabad High Court (IHC) has directed local authorities to ...

Psoriasis is a multifactorial immune-mediated inflammatory disease. Its pathogenesis involves abnormal accumulation of neutrophils and T-cell related abnormalities. Pyroptosis is a type of regulated ...